Company intelligence / Profile preview
Rampart Health
San Diego, California, United Statesramparthealth.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Rampart Health reported positive preliminary results from its first-in-human Phase 2 trial ("Abscopal 5001") of MITI in metastatic cancer. The treatment was safe and well tolerated as an outpatient procedure. Disease control rate was observed at 77% (partial response in ~39%, stable disease in ~39%), and the abscopal effect—regression of untreated metastases—was seen in about a third of patients. No grade 4 or higher adverse events were reported.
- Therapeutic areas
- Oncology
- Modalities
- Multiplex intra-tumoral immunotherapy (MITI)Combination of cryo-ablation, intra-tumoral checkpoint inhibitors, and local chemotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Rampart Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rampart Health.